AU2001245356A1 - Inhibitors of hepatitis c virus ns3 protease - Google Patents

Inhibitors of hepatitis c virus ns3 protease

Info

Publication number
AU2001245356A1
AU2001245356A1 AU2001245356A AU4535601A AU2001245356A1 AU 2001245356 A1 AU2001245356 A1 AU 2001245356A1 AU 2001245356 A AU2001245356 A AU 2001245356A AU 4535601 A AU4535601 A AU 4535601A AU 2001245356 A1 AU2001245356 A1 AU 2001245356A1
Authority
AU
Australia
Prior art keywords
hepatitis
protease
virus
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245356A
Inventor
Wei Han
Xiaojun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2001245356A1 publication Critical patent/AU2001245356A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
AU2001245356A 2000-02-29 2001-02-28 Inhibitors of hepatitis c virus ns3 protease Abandoned AU2001245356A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18561800P 2000-02-29 2000-02-29
US60185618 2000-02-29
PCT/US2001/006269 WO2001064678A2 (en) 2000-02-29 2001-02-28 Inhibitors of hepatitis c virus ns3 protease

Publications (1)

Publication Number Publication Date
AU2001245356A1 true AU2001245356A1 (en) 2001-09-12

Family

ID=22681735

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245356A Abandoned AU2001245356A1 (en) 2000-02-29 2001-02-28 Inhibitors of hepatitis c virus ns3 protease

Country Status (6)

Country Link
US (1) US6699855B2 (en)
EP (1) EP1261611A2 (en)
JP (1) JP2003525294A (en)
AU (1) AU2001245356A1 (en)
CA (1) CA2396504A1 (en)
WO (1) WO2001064678A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9712544B1 (en) 1996-10-18 2013-10-22 SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
US6846806B2 (en) * 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
WO2003087092A2 (en) 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
US7037911B2 (en) 2002-06-26 2006-05-02 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
CN1791599A (en) 2003-05-21 2006-06-21 贝林格尔.英格海姆国际有限公司 Hepatitis c inhibitor compounds
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2536182C (en) 2003-09-22 2012-07-24 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
KR20060130027A (en) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
ES2358333T3 (en) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh MACROCYCLIC PEPTIDES WITH ACTION AGAINST THE VIRUS OF HEPATITIS C.
AU2005212257A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
DE602005013922D1 (en) 2004-02-24 2009-05-28 Japan Tobacco Inc CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITOR
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
NZ565540A (en) * 2005-08-02 2011-06-30 Vertex Pharma Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
EP2364970A1 (en) 2005-08-19 2011-09-14 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP1951748B1 (en) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
JP5436864B2 (en) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Co-crystal containing VX-950 and pharmaceutical composition containing the same
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
SI2114924T1 (en) * 2007-02-27 2012-06-29 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
NZ579295A (en) * 2007-02-27 2012-03-30 Vertex Pharma Inhibitors of serine proteases
ES2381410T3 (en) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Combination therapy for the treatment of HCV infections
CN101835774B (en) * 2007-08-30 2014-09-17 弗特克斯药品有限公司 Co-crystals and pharmaceutical compositions comprising the same
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN116041581A (en) * 2021-10-28 2023-05-02 中国石油化工股份有限公司 Olefin polymerization catalyst component, preparation method and application thereof
CN116041586B (en) * 2021-10-28 2024-02-13 中国石油化工股份有限公司 Catalyst component for olefin polymerization, preparation method thereof, catalyst and olefin polymerization method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030396A1 (en) * 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
ATE206433T1 (en) * 1995-03-24 2001-10-15 Molecumetics Ltd BETA LOOP-LIKE COMPOUNDS AND THEIR USE AS PROTEASE INHIBITORS
US6124291A (en) * 1996-06-18 2000-09-26 Warner-Lambert Company Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors
NZ334227A (en) * 1996-08-05 2000-10-27 Molecumetics Ltd Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
BR9712544B1 (en) 1996-10-18 2013-10-22 SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES
US5962487A (en) * 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
WO1999041276A1 (en) * 1998-02-12 1999-08-19 Molecumetics Ltd. β-SHEET MIMETICS AND METHODS RELATING TO THE USE THEREOF
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
FR2795072B1 (en) * 1999-06-15 2001-07-27 Adir NOVEL BICYCLIC DERIVATIVES OF AMINO-PYRAZINONES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
WO2001064678A3 (en) 2002-03-07
CA2396504A1 (en) 2001-09-07
US6699855B2 (en) 2004-03-02
JP2003525294A (en) 2003-08-26
EP1261611A2 (en) 2002-12-04
US20020065248A1 (en) 2002-05-30
WO2001064678A2 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
AU2002230763A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2001280640A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
GB0107924D0 (en) Inhibitor of hepatitis C virus NS3 protease
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
HK1058047A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
IL153669A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
IL155842A0 (en) Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001282922A1 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
IL151934A0 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
HK1023779A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
IL174459A0 (en) Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
AU2003259155A1 (en) Pharmaceutical compositions comprising hepatitis c viral protease inhibitors
AU2933797A (en) Synthetic inhibitors of hepatitis c virus ns3 protease
AU7063598A (en) Hepatitis c ns3 protease inhibitors
IL162815A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AU1324300A (en) Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
EP1141255A4 (en) Modified forms of hepatitis c virus ns3 protease
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection